(Total Views: 157)
Posted On: 05/08/2020 12:13:38 PM
Post# of 25387
“We model CY22 EPS of $0.12 and apply a conservative 15x PE multiple to arrive at an intrinsic value of $1.82/share.”
Strong fundamentals and cheap valuation make a compelling investment case. We expect $IDEX’s top line to climb from $39 million in CY20 (back-half ended) to $89 million in CY22. Gross margin will remain stable around ~95% while EBITDA margin is likely to expand from ~23% in CY20 to ~32% in CY22 as the company benefits from economies of scale. More importantly, IDEX will generate positive FCF starting this year and its RoE will reach 28% by CY22. We model CY22 EPS of $0.12 and apply a conservative 15x PE multiple to arrive at an intrinsic value of $1.82/share.
Source: Intro-Act Analyst Report April 20,2020
Copyright: Copyright 2019 Intro-act, LLC (Intro-act).
Strong fundamentals and cheap valuation make a compelling investment case. We expect $IDEX’s top line to climb from $39 million in CY20 (back-half ended) to $89 million in CY22. Gross margin will remain stable around ~95% while EBITDA margin is likely to expand from ~23% in CY20 to ~32% in CY22 as the company benefits from economies of scale. More importantly, IDEX will generate positive FCF starting this year and its RoE will reach 28% by CY22. We model CY22 EPS of $0.12 and apply a conservative 15x PE multiple to arrive at an intrinsic value of $1.82/share.
Source: Intro-Act Analyst Report April 20,2020
Copyright: Copyright 2019 Intro-act, LLC (Intro-act).
(0)
(0)Scroll down for more posts ▼
